Sheryl Stevenson

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of Ophthalmology Times, Ophthalmology Times Europe, Modern Retina and Optometry Times. Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s EMPOWER Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for Crain's Cleveland Business Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.


Dr. Pomerance: How the mix of medicine and surgery attracted him to ophthalmology

Tennessee Academy of Ophthalmology’s doctor of the month shares what excites him about ophthalmology, his biggest career challenge, and chocolate as his favorite comfort food.

Last call: OWL’s 2022 Business & Leadership Trends Survey

Participate by May 20 in the annual Ophthalmic Business and Leadership Trends Survey for 2022.

Wills Eye Hospital promotes Dr. Kammi Gunton to chief of pediatric ophthalmology service

Expansion of program aims to provide more children with improved eye care; enhance the teaching of Wills residents and fellows

Study: Effects of two dosing regimens of Netarsudil in patients with Fuchs corneal dystrophy

April 23, 2022

Richard L. Lindstrom, MD, of Minnesota Eye Consultants, discusses his ASCRS presentation, "Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy," with Ophthalmology Times' Sheryl Stevenson.

Orasis phase 2b data for CSF-1 presented at ASCRS

April 23, 2022

For the first time, Orasis Pharmaceutical's phase 2b data for the company's novel candidate for the treatment of presbyopia, CSF-1, a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle, will be presented during ASCRS by Marjan Farid, MD, and Preeya Gupta, MD. The company recently released its phase 3 topline results. Orasis' Paul Smith, president and COO, talks with Ophthalmology Times' Sheryl Stevenson about this data and the findings' relevance to patients and providers.